These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25107463)

  • 1. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
    Hasegawa T; Aisa Y; Shimazaki K; Nakazato T
    Ann Hematol; 2015 Mar; 94(3):515-7. PubMed ID: 25107463
    [No Abstract]   [Full Text] [Related]  

  • 2. Bendamustine can severely impair T-cell immunity against cytomegalovirus.
    Hosoda T; Yokoyama A; Yoneda M; Yamamoto R; Ohashi K; Kagoo T; Ueno H; Boku S; Yano T
    Leuk Lymphoma; 2013 Jun; 54(6):1327-8. PubMed ID: 23072371
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy].
    Mitsumori T; Sueki Y; Kawashima I; Yamamoto T; Nozaki Y; Nakajima K; Kirito K
    Rinsho Ketsueki; 2014 Feb; 55(2):239-43. PubMed ID: 24598192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
    Isono N; Imai Y; Watanabe A; Moriya K; Tamura H; Inokuchi K; Asano C; Masuda M; Shimura H; Mitsuhashi K; Kazama H; Sugimori H; Motoji T; Tanaka J
    Leuk Lymphoma; 2016 Sep; 57(9):2204-7. PubMed ID: 26699798
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine.
    Lim SH; Pathapati S; Langevin J; Hoot A
    Ann Hematol; 2012 Apr; 91(4):643-4. PubMed ID: 21811782
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2017 Jul; 96(7):1215-1217. PubMed ID: 28447162
    [No Abstract]   [Full Text] [Related]  

  • 7. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMV Pneumonitis following Bendamustine containing Chemotherapy.
    Singhania SVK; Parikh P; Goyle S
    J Assoc Physicians India; 2017 Sep; 65(9):92-93. PubMed ID: 29313585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
    Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stevens-Johnson syndrome after treatment with bendamustine.
    Lambertini M; Del Mastro L; Gardin G; Levaggi A; Bighin C; Giraudi S; Pronzato P
    Leuk Res; 2012 Jul; 36(7):e153-4. PubMed ID: 22480970
    [No Abstract]   [Full Text] [Related]  

  • 11. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
    Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
    Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized cytomegalovirus reactivation after radiotherapy for high-grade gastric lymphoma.
    Saga K; Fukui T; Kato Y; Komeda T; Nakase H; Watanabe N; Nishio A; Chiba T
    Gastrointest Endosc; 2007 Mar; 65(3):545-7. PubMed ID: 17321266
    [No Abstract]   [Full Text] [Related]  

  • 13. [Recommendation for the optimal use of bendamustine in Japan].
    Ohmachi K; Maruyama D; Nisikori M; Suzuki T; Izutsu K
    Rinsho Ketsueki; 2014 Mar; 55(3):311-20. PubMed ID: 24681934
    [No Abstract]   [Full Text] [Related]  

  • 14. Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect.
    Malipatil B; Ganesan P; Sundersingh S; Sagar TG
    Hematol Oncol Stem Cell Ther; 2011; 4(4):157-60. PubMed ID: 22198186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine-induced "flagellate dermatitis".
    Mahmoud BH; Eide MJ
    Dermatol Online J; 2012 Nov; 18(11):12. PubMed ID: 23217953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
    Meije Y; Lizasoain M; García-Reyne A; Martínez P; Rodríguez V; López-Medrano F; Juan RS; Lalueza A; Aguado JM
    Clin Infect Dis; 2010 Jun; 50(12):e73-6. PubMed ID: 20455691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine.
    Chiba A; Nakamura F; Nakazaki K; Kurokawa M
    Leuk Lymphoma; 2018 Mar; 59(3):749-751. PubMed ID: 28697686
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.
    Corazzelli G; Angrilli F; D'Arco A; Ferrara F; Musto P; Guarini A; Cox MC; Stelitano C; Storti S; Iannitto E; Falorio S; Califano C; Amore A; Arcamone M; De Filippi R; Pinto A
    Br J Haematol; 2013 Jan; 160(2):207-15. PubMed ID: 23167437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal ongoing human cytomegalovirus reactivation during high-dose melphalan and autologous stem cell transplantation.
    Focosi D; Sordi E; Papineschi F; Benedetti E; Galimberti S; Petrini M
    J Med Virol; 2009 May; 81(5):857-60. PubMed ID: 19319946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
    Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
    Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.